Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and Melphalan with ASCT for Multiple Myeloma
NCT01142232Phase 2Completed
- Start
- Aug 2010
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM). Primary endpoints: Number of Patients With Dose Limiting Toxicity at 1 month and Overall Response Rate at 5 years. Started Aug 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01142232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142232.